Small Animal Studies Core Shared Resource ABSTRACT The Small Animal Studies Core (SASC) combines the resources available through the previously reviewed Small Animal Imaging Core with a new Animal Tumor Models component. This combined resource provides exceptional quality services for City of Hope Comprehensive Cancer Center (COHCCC) members for basic and translational preclinical studies in cancer biology, anti-cancer drug development, and stem cell therapeutic development. The Small Animal Imaging component of the SASC provides consultation, advanced imaging equipment, imaging services, hands-on training for COHCCC members, and support for protocol and grant preparation. Current systems in the Imaging Laboratory include two units for bioluminescence/fluorescence optical imaging (Ami X and Lago X from Spectral Instruments Imaging) and a PET/SPECT/CT trimodal scanner (Inveon from Siemens). These systems support molecular-based imaging to allow for the monitoring of cellular processes and the non-invasive assessment of pharmacokinetics and pharmacodynamics of therapeutic agents. Often the imaging techniques and targeting agents utilized are directly transferable to the clinical setting. The Animal Tumor Models component of the SASC has established patient-derived xenograft (PDX) models of breast, colorectal, lung, sarcoma, and gastric cancers in collaboration with COHCCC physician scientists and has developed next-generation humanized mouse models for research in cancer immunotherapy and in vivo drug metabolism/toxicity studies. The development of PDX models supports precision medicine by allowing investigators to evaluate tumor growth and therapeutic response for individual patients. The Animal Tumor Models component also provides specialized drug delivery services, training for in vivo procedures, and support for protocol preparation and grant development. The SASC is co-directed by Dr. David Colcher, a Professor in the Department of Molecular Immunology, and Dr. Jun Wu, an Associate Research Professor of Comparative Medicine, and is supported by highly qualified staff that maintain and operate the instrumentation. Oversight is provided by an interdisciplinary faculty Advisory Committee, and user feedback through an annual survey. The SASC occupies three rooms within the 29,000 sq. ft. Parvin Building for animal experiments and two rooms in Huntington Lab for tumor cell and reagent preparation. iLab software is used to schedule services, monitor instrument use, and manage billing within the SASC. Over the previous five years, the SASC was used by 80 unique investigators, including 58 CC members. Of the 58 CC members, 48 (83%) had peer-reviewed funding. As of this report, the SASC provides ongoing support to 12 NIH-funded projects totaling $5.6M per year in direct costs to the COHCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-35
Application #
9491626
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-04-20
Budget End
2018-11-30
Support Year
35
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835
Chiuppesi, Flavia; Nguyen, Jenny; Park, Soojin et al. (2018) Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol 92:
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609

Showing the most recent 10 out of 1396 publications